A new stent design for targeted drug delivery to prevent blood vessel narrowing
A Retrievable, Chambered Stentgraft to Achieve Localized, High Intensity Drug Delivery for Treatment of Vascular Restenosis
This study is testing a new type of stent that helps deliver medicine directly to blood vessels after procedures like angioplasty, aiming to prevent them from narrowing again while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10979687 on NIH RePORTER |
What this research studies
This research investigates a novel stent design that aims to improve drug delivery directly to blood vessels after procedures like angioplasty. The Retrievable Drug Delivery Stentgraft (RDDS) is designed to isolate the treatment area and deliver medication effectively while minimizing systemic exposure. By using a specialized polymer covering and a unique shape, the stent can infuse drugs only where needed, potentially reducing the risk of complications associated with traditional methods. This approach addresses the common issue of restenosis, where blood vessels narrow again after treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone angioplasty or stenting and are at risk for restenosis.
Not a fit: Patients who have not had vascular interventions or those with conditions unrelated to blood vessel narrowing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of restenosis and improve long-term outcomes for patients undergoing vascular interventions.
How similar studies have performed: Other research has shown promise with targeted drug delivery systems in vascular treatments, suggesting that this approach could be effective.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Tillman, Bryan W. — Ohio State University
- Study coordinator: Tillman, Bryan W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.